Lexaria Bioscience Corp (LEXX) Q4 2024 Earnings Report

Lexaria Bioscience Corp (LEXX) reported Q4 2024 results that underscore a company in the pre-revenue, IP-driven growth phase. Revenue stood at $84,000 with a gross margin of 100% as cost of revenue was nil, but the company incurred substantial operating expenses, including $967,206 in R&D and $1,319,858 in G&A, resulting in an EBITDA of $(2.20) million and a net loss of $(2.18) million for the quarter. Basic earnings per share were $(0.17). The quarterly cash flow profile shows a negative operating cash flow of $(1.89) million and a free cash flow of $(1.96) million, with capital expenditures of $(69,587). The company funded its activities through financing that included $9.25 million of common stock issued, yielding a net cash inflow of $4.21 million from financing activities; however, the net change in cash for the quarter was a reduction of $(1.96) million, leaving cash and cash equivalents at $6.50 million at period end. The balance sheet remains lightly levered with minimal debt (total debt $137k) and a robust current ratio of 7.18, resulting in a net cash position of roughly $6.36 million. Importantly, Lexaria’s strategic value lies in its DehydraTECH patent portfolio (23 patents granted with ~50 pending) and the potential to monetize through licensing and collaborations as the company expands its applications beyond cannabinoids and nicotine into antivirals, NSAIDs, PDE5 inhibitors, and other drugs. With no explicit quarterly forward guidance in the QQ4 filing, the near-term driver of value will be the timing and terms of licensing agreements and IP monetization milestones. Given the current scale, the stock remains highly sensitive to financing activity and biomarker-driven progress in its IP pipeline. Overall, the quarter reinforces a classic early-stage biotech profile: strong IP potential and liquidity against a backdrop of ongoing operating losses and revenue ramp risk.